In Silico Drug Repurposing: Integrating Network Pharmacology and Structure-Based Virtual Screening to Accelerate Preclin

Preprints.org · 2026-11-05 · 预印本

De novo drug discovery requires over a decade of research and $1.5 billion to $2.5 billion in investment per approved molecule, yet more than 90% of candidates fail during clinical trials due to unforeseen toxicity or poor efficacy. In silico drug repurposing offers a faster, cost-effective alternative by finding new therapeutic uses for regulatory-approved or clinical-stage molecules. However, individual computation…

（中文解读待补写）

🔗 打开原文

Abdullah Al Nayem, Sheikh Tarikul Islam Tusher, Sanjoy Deb

本文摘自《每日前沿研究简报 · 2026-11-07》「化学信息 / 药物发现」。本内容仅用于研究信息整理与科普交流，不构成医疗建议。